access pharma logo Access Pharmaceuticals

  • About Us
    • Board of Directors
    • Senior Management
  • Product Programs
    • MuGard
    • ProLindac
      • Chemistry
      • Preclinical data
      • Future Development
    • Cobalamin mediated oral drug delivery
    • Thiarabine
    • Cobalamin targeted delivery
    • Publications
  • Business Development
  • Investor Relations
  • Newsroom
    • 2010
    • 2009
  • Contact Us
flash placeholder

Product Programs

  • MuGard
  • ProLindac
  • Cobalamin mediated oral drug delivery
  • Thiarabine
  • Cobalamin targeted delivery
  • Publications

Product Pipeline

  • Sign up for news alerts!

  • Latest Product Programs News & Events

    • 06.15.10
      Access Pharma Initiates U.S. MuGard Sampling Program With Leading Oncology Groups
    • 06.10.10
      Access Pharma Presents at the California Nanosystems Institute Conference Focused on Targeted Delivery of RNAi Therapeutics
    • 04.15.10
      Access Pharma Collaborates With Leading Oral Mucositis Expert to Further Support MuGard Commercialization Efforts
    • 04.13.10
      Access Pharma Announces Successful Completion of First North American MuGard Commercial Production Run
    • 03.25.10
      Access Pharma's Korean Partner Gains Marketing Approval for MuGard
    More News
© Access Pharmaceuticals 2009 | Disclaimer